Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | ACE | P12821 | 6/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19990693 | 0.93 | L3MBTL1 (0.43) | L3MBTL1ACEHSD11B1JAK2JAK1 | |
| SCHEMBL17956403 | 0.90 | ACE (0.35) | L3MBTL1ACEFKBP1ALMNAAGTR2 | |
| SCHEMBL26910204 | 0.87 | CHRM5 (0.44) | ACEFKBP1AAGTR2 | |
| SCHEMBL24358362 | 0.87 | JAK2 (0.40) | L3MBTL1ACEHSD11B1JAK2JAK1 | |
| SCHEMBL22602153 | 0.87 | JAK2 (0.40) | L3MBTL1ACEHSD11B1JAK2JAK1 | |
| SCHEMBL17956550 | 0.84 | AGTR2 (0.39) | ACEAGTR2 | |
| SCHEMBL20009192 | 0.82 | KLK7 (0.42) | L3MBTL1ACEHSD11B1JAK2JAK1 | |
| SCHEMBL17956515 | 0.81 | FKBP1A (0.34) | L3MBTL1FKBP1A | |
| SCHEMBL3665151 | 0.80 | AGTR2 (0.39) | AGTR2 | |
| SCHEMBL19990855 | 0.80 | UBE2M (0.42) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3698796-B1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | NOVARTIS AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3698796-A1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | Novartis AG (CH) | 2020-08-26 | — | — | EP | disclosed |
| EP-3519419-B1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2020-05-27 | — | — | EP | disclosed |
| US-10597396-B2 | Beta-lactamase inhibitors | NOVARTIS AG (CH) | 2020-03-24 | — | — | US | disclosed |
| EP-3519419-A1 | BETA-LACTAMASE INHIBITORS | Novartis AG (CH) | 2019-08-07 | — | — | EP | disclosed |
| US-20190177324-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2019-06-13 | — | — | US | disclosed |
| US-10065957-B2 | Beta-lactamase inhibitors | NOVARTIS AG (CH) | 2018-09-04 | — | — | US | disclosed |
| WO-2018060926-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-04-05 | — | — | WO | disclosed |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177324-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | L3MBTL1 458/4885ACE 29/4885HSD11B1 312/4885 |
| US-10597396-B2 | Beta-lactamase inhibitors | MGAM, LCT, GAA | L3MBTL1 458/4885ACE 29/4885HSD11B1 312/4885 |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | L3MBTL1 458/4885ACE 29/4885HSD11B1 312/4885 |
| US-10065957-B2 | Beta-lactamase inhibitors | MGAM, LCT, GAA | L3MBTL1 458/4885ACE 29/4885HSD11B1 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.